European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.

Packaging 111

Packaging Pharmaceutical Manufacturing Diabetes 111

European Pharmaceutical Review

DECEMBER 18, 2023

Additionally, in October, EPR shared Phase III trial data for the type 1 diabetes treatment TZIELD (Teplizumab), which suggested that the medicine could slow disease progression. The year 2023 also brought much advancement in the Alzheimer’s space for the pharmaceutical industry.

Pharmaceutical Manufacturing 98

Pharmaceutical Manufacturing Hospitals Diabetes 98

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. A respiratory platform similar to the diabetes one, the Digital Health Solution is yet another future-looking inclusion in the Chiesi plan.

Drug Development 98

Drug Development Pharmaceutical Manufacturing Diabetes 98